Seasonal Migration and Home Ranges of Female Elk in the Black Hills of South Dakota and Wyoming

Understanding the movement and dispersion patterns of elk (Cervus elaphus) on public lands and the underlying factors that affect each will facilitate elk management and help resolve conflicts between management that benefit elk and other uses of land resources. Consequently, there is a need to identify and examine the movement and dispersion patterns of elk in the Black Hills of South Dakota and Wyoming. Our study quantified seasonal movements, determined home ranges of female elk in two areas of the Black Hills, and examined underlying factors associated with each. Elk in the northern area did not demonstrate seasonal migration patterns. Rather, winter ranges in the northern area were contained mostly within the boundaries of the summer range. Elk in the southern area exhibited a north-south migration pattern that coincided with seasonal patterns of snowfall. These elk migrated to winter range in late November and returned to summer range in late April. Home ranges of elk in the southern area were larger (P \u3c 0.01) than home ranges in the northern area. Landscape characteristics with marginally-significant correlations to elk home range area included road density (P = 0.10), and forage:cover ratio (P = 0.08); density of primary and secondary roads and average slope were significantly correlated with elk home range area (P \u3c 0.01). Managers can use this information to develop strategies that meet population goals and reduce conflicts between management for elk and with other resources

Seasonal Migration and Home Ranges of Female Elk in the Black Hills of South Dakota and Wyoming

Understanding the movement and dispersion patterns of elk (Cervus elaphus) on public lands and the underlying factors that affect each will facilitate elk management and help resolve conflicts between management that benefit elk and other uses of land resources. Consequently, there is a need to identify and examine the movement and dispersion patterns of elk in the Black Hills of South Dakota and Wyoming. Our study quantified seasonal movements, determined home ranges of female elk in two areas of the Black Hills, and examined underlying factors associated with each. Elk in the northern area did not demonstrate seasonal migration patterns. Rather, winter ranges in the northern area were contained mostly within the boundaries of the summer range. Elk in the southern area exhibited a north-south migration pattern that coincided with seasonal patterns of snowfall. These elk migrated to winter range in late November and returned to summer range in late April. Home ranges of elk in the southern area were larger (P \u3c 0.01) than home ranges in the northern area. Landscape characteristics with marginally-significant correlations to elk home range area included road density (P = 0.10), and forage:cover ratio (P = 0.08); density of primary and secondary roads and average slope were significantly correlated with elk home range area (P \u3c 0.01). Managers can use this information to develop strategies that meet population goals and reduce conflicts between management for elk and with other resources

Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Among Hospitalized Adults Aged ≥65 Years — United States, January–March 2021

Adults aged ≥65 years are at increased risk for severe outcomes from COVID-19 and were identified as a priority group to receive the first COVID-19 vaccines approved for use under an Emergency Use Authorization (EUA) in the United States (1-3). In an evaluation at 24 hospitals in 14 states,* the effectiveness of partial or full vaccination† with Pfizer-BioNTech or Moderna vaccines against COVID-19-associated hospitalization was assessed among adults aged ≥65 years. Among 417 hospitalized adults aged ≥65 years (including 187 case-patients and 230 controls), the median age was 73 years, 48% were female, 73% were non-Hispanic White, 17% were non-Hispanic Black, 6% were Hispanic, and 4% lived in a long-term care facility. Adjusted vaccine effectiveness (VE) against COVID-19-associated hospitalization among adults aged ≥65 years was estimated to be 94% (95% confidence interval [CI] = 49%-99%) for full vaccination and 64% (95% CI = 28%-82%) for partial vaccination. These findings are consistent with efficacy determined from clinical trials in the subgroup of adults aged ≥65 years (4,5). This multisite U.S. evaluation under real-world conditions suggests that vaccination provided protection against COVID-19-associated hospitalization among adults aged ≥65 years. Vaccination is a critical tool for reducing severe COVID-19 in groups at high risk

Vaccine effectiveness of primary series and booster doses against covid-19 associated hospital admissions in the United States: living test negative design study

AbstractObjectiveTo compare the effectiveness of a primary covid-19 vaccine series plus booster doses with a primary series alone for the prevention of hospital admission with omicron related covid-19 in the United States.DesignMulticenter observational case-control study with a test negative design.SettingHospitals in 18 US states.Participants4760 adults admitted to one of 21 hospitals with acute respiratory symptoms between 26 December 2021 and 30 June 2022, a period when the omicron variant was dominant. Participants included 2385 (50.1%) patients with laboratory confirmed covid-19 (cases) and 2375 (49.9%) patients who tested negative for SARS-CoV-2 (controls).Main outcome measuresThe main outcome was vaccine effectiveness against hospital admission with covid-19 for a primary series plus booster doses and a primary series alone by comparing the odds of being vaccinated with each of these regimens versus being unvaccinated among cases versus controls. Vaccine effectiveness analyses were stratified by immunosuppression status (immunocompetent, immunocompromised). The primary analysis evaluated all covid-19 vaccine types combined, and secondary analyses evaluated specific vaccine products.ResultsOverall, median age of participants was 64 years (interquartile range 52-75 years), 994 (20.8%) were immunocompromised, 85 (1.8%) were vaccinated with a primary series plus two boosters, 1367 (28.7%) with a primary series plus one booster, and 1875 (39.3%) with a primary series alone, and 1433 (30.1%) were unvaccinated. Among immunocompetent participants, vaccine effectiveness for prevention of hospital admission with omicron related covid-19 for a primary series plus two boosters was 63% (95% confidence interval 37% to 78%), a primary series plus one booster was 65% (58% to 71%), and for a primary series alone was 37% (25% to 47%) (P<0.001 for the pooled boosted regimens compared with a primary series alone). Vaccine effectiveness was higher for a boosted regimen than for a primary series alone for both mRNA vaccines (BNT162b2 (Pfizer-BioNTech): 73% (44% to 87%) for primary series plus two boosters, 64% (55% to 72%) for primary series plus one booster, and 36% (21% to 48%) for primary series alone (P<0.001); mRNA-1273 (Moderna): 68% (17% to 88%) for primary series plus two boosters, 65% (55% to 73%) for primary series plus one booster, and 41% (25% to 54%) for primary series alone (P=0.001)). Among immunocompromised patients, vaccine effectiveness for a primary series plus one booster was 69% (31% to 86%) and for a primary series alone was 49% (30% to 63%) (P=0.04).ConclusionDuring the first six months of 2022 in the US, booster doses of a covid-19 vaccine provided additional benefit beyond a primary vaccine series alone for preventing hospital admissions with omicron related covid-19.Readers’ noteThis article is a living test negative design study that will be updated to reflect emerging evidence. Updates may occur for up to two years from the date of original publication